BEYOND LIFE-CHANGING   
PHARMACEUTICAL SOLUTIONS

OLTRE BIOMEDICAL

PRESENTS

CAVALTINIB™

Statue with Mask

OUR MISSION

OLTRE BIOMEDICAL Inc. was established with the expressed purpose of funding and pursuing clinical trials in Canada and the USA for its promising drug treatment for respiratory diseases.

 

In 2022, the more immediate interest and focus will be on the urgently needed treatment of COVID-19 patients in distress.

EXPLORING CAVALTINIB™

Cavaltinib™  has been shown in published research to inhibit the cytokines responsible for the ‘cytokine storm’ phenomenon at a central upstream mechanism that reduces the transcription (production) of many causal cytokines that drive these diseased states.

 

This work has subsequently led to approval by Health Canada for a clinical trial for what appears to be a good COVID-19 drug candidate.

 

   

Covid 19

A MESSAGE FROM THE CEO